Stock QLGN QUALIGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qualigen Therapeutics, Inc.

Equities

QLGN

US74754R2022

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.2905 USD -2.19% Intraday chart for Qualigen Therapeutics, Inc. -8.65% -47.18%
Apr. 16 Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft? CI
Apr. 08 Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 37.76 5.428 2.85 1.832 -
Enterprise Value (EV) 1 37.76 5.428 2.85 1.832 1.832
P/E ratio -1.75 x -0.27 x -0.21 x -0.29 x -0.41 x
Yield - - - - -
Capitalization / Revenue 6.68 x 1.09 x 0.78 x - -
EV / Revenue 6.68 x 1.09 x 0.78 x - -
EV / EBITDA - - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 3,529 4,211 5,181 6,307 -
Reference price 2 10.70 1.289 0.5500 0.2905 0.2905
Announcement Date 3/31/22 5/2/23 4/8/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 5.654 4.984 3.661 - -
EBITDA - - - - -
EBIT 1 -22.66 -17.94 -11.3 -11 -11.4
Operating Margin -400.85% -360.03% -308.78% - -
Earnings before Tax (EBT) 1 -17.89 -21.3 -12.48 -11 -11.4
Net income 1 -17.9 -18.64 -13.42 -11 -11.4
Net margin -316.55% -374.04% -366.48% - -
EPS 2 -6.100 -4.850 -2.650 -1.000 -0.7100
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/31/22 5/2/23 4/8/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 1.155 1.481 0.722 1.431 1.441 1.39 1.607 1.627 0.4269 -
EBITDA - - - - - - - - - -
EBIT 1 -4.808 -4.647 -5.009 -4.141 -4.383 -4.409 -3.693 -3.551 -2.778 -2.274
Operating Margin -416.24% -313.76% -693.69% -289.5% -304.15% -317.25% -229.77% -218.26% -650.79% -
Earnings before Tax (EBT) 1 -2.858 -6.057 -4.319 -4.122 -4.056 -8.803 -4.271 -3.546 -3.235 -2.472
Net income 1 -2.859 -6.061 -4.32 -4.123 -3.825 -6.372 -3.846 -3.464 -3.657 -2.45
Net margin -247.48% -409.17% -598.28% -288.24% -265.44% -458.46% -239.32% -212.92% -856.49% -
EPS 2 -1.000 -2.000 -1.200 -1.100 -1.000 -1.550 -0.7800 -0.6900 -0.7200 -0.4700
Dividend per Share - - - - - - - - - -
Announcement Date 11/15/21 3/31/22 5/13/22 8/15/22 11/14/22 5/2/23 5/15/23 8/14/23 11/14/23 4/8/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 3/31/22 5/2/23 4/8/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
QUALIGEN THERAPEUTICS, INC. Stock Qualigen Therapeutics, Inc.
-47.18% 1.83M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. QLGN Stock
  4. Financials Qualigen Therapeutics, Inc.